Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease

European Journal of Neuroscience

Volumn 39, Issue 6, 2014, Pages 1042-1056

  Stott, Simon R W ^a   Barker, Roger A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

6 OHDA; Dopamine; Neurodegeneration; Parkinson's disease; Substantia nigra

Indexed keywords

ALDEHYDE DEHYDROGENASE; DOPAMINE; OXIDOPAMINE; TRANSCRIPTION FACTOR; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL SIZE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DENDRITE; DOPAMINERGIC SYSTEM; FEMALE; MESENCEPHALON; MICROGLIA; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRIATE CORTEX; SUBSTANTIA NIGRA;

6-OHDA; DOPAMINE; NEURODEGENERATION; PARKINSON'S DISEASE; SUBSTANTIA NIGRA;

ALDEHYDE DEHYDROGENASE; ANIMALS; ASTROCYTES; CORPUS STRIATUM; DENDRITES; DOPAMINERGIC NEURONS; FEMALE; MICE; MICE, INBRED C57BL; OXIDOPAMINE; PARKINSON DISEASE; SUBSTANTIA NIGRA; TIME FACTORS; TRANSCRIPTION FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84896112929     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/ejn.12459     Document Type: Article

References (79)

1. Akerud, P., Canals, J.M., Snyder, E.Y. & Arenas, E. (2001) Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J. Neurosci., 21, 8108-8118.
2. Alvarez-Fischer, D., Henze, C., Strenzke, C., Westrich, J., Ferger, B., Hoglinger, G.U., Oertel, W.H. & Hartmann, A. (2008) Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp. Neurol., 210, 182-193.
3. Ambrosi, G., Armentero, M.T., Levandis, G., Bramanti, P., Nappi, G. & Blandini, F. (2010) Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease. Brain Res. Bull., 82, 29-38.
4. Ang, S.L. (2006) Transcriptional control of midbrain dopaminergic neuron development. Development, 133, 3499-3506.
5. Bensadoun, J.C., Deglon, N., Tseng, J.L., Ridet, J.L., Zurn, A.D. & Aebischer, P. (2000) Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp. Neurol., 164, 15-24.
6. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K. & Seitelberger, F. (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci., 20, 415-455.
7. Bernstein, A.I., Garrison, S.P., Zambetti, G.P. & O'Malley, K.L. (2011) 6-OHDA generated ROS induces DNA damage and p53- and PUMA-dependent cell death. Mol. Neurodegener., 6, 2.
8. Blandini, F., Levandis, G., Bazzini, E., Nappi, G. & Armentero, M.-T. (2007) Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. Eur. J. Neurosci., 25, 397-405.
9. Brundin, P., Isacson, O., Gage, F.H., Prochiantz, A. & Bjorklund, A. (1986) The rotating 6-hydroxydopamine-lesioned mouse as a model for assessing functional effects of neuronal grafting. Brain Res., 366, 346-349.
10. Carlsson, T., Carta, M., Winkler, C., Bjorklund, A. & Kirik, D. (2007) Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci., 27, 8011-8022.
11. Cunningham, L.A. & Su, C. (2002) Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Exp. Neurol., 174, 230-242.
12. Cutillas, B., Espejo, M., Gil, J., Ferrer, I. & Ambrosio, S. (1999) Caspase inhibition protects nigral neurons against 6-OHDA-induced retrograde degeneration. NeuroReport, 10, 2605-2608.
13. Decressac, M., Mattsson, B., Lundblad, M., Weikop, P. & Bjorklund, A. (2012) Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha-synuclein in midbrain dopamine neurons. Neurobiol. Dis., 45, 939-953.
14. Depino, A.M., Earl, C., Kaczmarczyk, E., Ferrari, C., Besedovsky, H., del Rey, A., Pitossi, F.J. & Oertel, W.H. (2003) Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur. J. Neurosci., 18, 2731-2742.
15. Di Salvio, M., Di Giovannantonio, L.G., Acampora, D., Prosperi, R., Omodei, D., Prakash, N., Wurst, W. & Simeone, A. (2010) Otx2 controls neuron subtype identity in ventral tegmental area and antagonizes vulnerability to MPTP. Nat. Neurosci., 13, 1481-1488.
16. Diaz-Ruiz, O., Zapata, A., Shan, L., Zhang, Y., Tomac, A.C., Malik, N., de la Cruz, F. & Backman, C.M. (2009) Selective deletion of PTEN in dopamine neurons leads to trophic effects and adaptation of striatal medium spiny projecting neurons. PLoS ONE, 4, e7027.
17. Domanskyi, A., Geissler, C., Vinnikov, I.A., Alter, H., Schober, A., Vogt, M.A., Gass, P., Parlato, R. & Schutz, G. (2011) Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson's disease models. FASEB J., 25, 2898-2910.
18. Duty, S. & Jenner, P. (2011) Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Brit. J. Pharmacol., 164, 1357-1391.
19. Ebert, A.D., Hann, H.J. & Bohn, M.C. (2008) Progressive degeneration of dopamine neurons in 6-hydroxydopamine rat model of Parkinson's disease does not involve activation of caspase-9 and caspase-3. J. Neurosci. Res., 86, 317-325.
20. Fearnley, J.M. & Lees, A.J. (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain, 114(Pt. 5), 2283-2301.
21. Gonzalez-Scarano, F. & Baltuch, G. (1999) Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci., 22, 219-240.
22. Grealish, S., Xie, L., Kelly, M. & Dowd, E. (2008) Unilateral axonal or terminal injection of 6-hydroxydopamine causes rapid-onset nigrostriatal degeneration and contralateral motor impairments in the rat. Brain Res. Bull., 77, 312-319.
23. Grealish, S., Mattsson, B., Draxler, P. & Bjorklund, A. (2010) Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. Eur. J. Neurosci., 31, 2266-2278.
24. Guillery, R.W. & Herrup, K. (1997) Quantification without pontification: choosing a method for counting objects in sectioned tissues. J. Comp. Neurol., 386, 2-7.
25. Hanrott, K., Murray, T.K., Orfali, Z., Ward, M., Finlay, C., O'Neill, M.J. & Wonnacott, S. (2008) Differential activation of PKC delta in the substantia nigra of rats following striatal or nigral 6-hydroxydopamine lesions. Eur. J. Neurosci., 27, 1086-1096.
26. Herkenham, M., Little, M.D., Bankiewicz, K., Yang, S.C., Markey, S.P. & Johannessen, J.N. (1991) Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience, 40, 133-158.
27. Hernandez-Baltazar, D., Mendoza-Garrido, M.E. & Martinez-Fong, D. (2013) Activation of GSK-3beta and Caspase-3 Occurs in Nigral Dopamine Neurons during the Development of Apoptosis Activated by a Striatal Injection of 6-Hydroxydopamine. PLoS ONE, 8, e70951.
28. Heuer, A., Smith, G.A., Lelos, M.J., Lane, E.L. & Dunnett, S.B. (2012) Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: motor impairments identify extent of dopamine depletion at three different lesion sites. Behav. Brain Res., 228, 30-43.
29. Hökfelt, T., Martensson, R., Björklund, A., Kleinan, S. & Goldstein, M. (1984) Distributional of tyrosine hydroxylase-immunoreactive neurons in the rat brain. In Björklund, A. & Hökfelt, T. (Eds), Handbook of Chemical Neuroanatomy (Classical Transmitters in the CNS, Part I). Elsevier, Amsterdam, the Netherlands, pp. 277-379.
30. Holtz, W.A., Turetzky, J.M. & O'Malley, K.L. (2005) Microarray expression profiling identifies early signaling transcripts associated with 6-OHDA-induced dopaminergic cell death. Antioxid. Redox Sign., 7, 639-648.
31. Houlden, H. & Singleton, A.B. (2012) The genetics and neuropathology of Parkinson's disease. Acta Neuropathol., 124, 325-338.
32. Hunt, D., Raivich, G. & Anderson, P.N. (2012) Activating transcription factor 3 and the nervous system. Front. Mol. Neurosci., 5, 7.
33. Iancu, R., Mohapel, P., Brundin, P. & Paul, G. (2005) Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav. Brain Res., 162, 1-10.
34. Inamoto, T., Czerniak, B.A., Dinney, C.P. & Kamat, A.M. (2010) Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. Cancer, 116, 340-346.
35. Iwata, S., Nomoto, M., Morioka, H. & Miyata, A. (2004) Gene expression profiling in the midbrain of striatal 6-hydroxydopamine-injected mice. Synapse, 51, 279-286.
36. Jacobs, F.M.J., Smits, S.M., Noorlander, C.W., von Oerthel, L., van der Linden, A.J.A., Burbach, J.P.H. & Smidt, M.P. (2007) Retinoic acid counteracts developmental defects in the substantia nigra caused by Pitx3 deficiency. Development, 134, 2673-2684.
37. Jeon, B.S., Jackson-Lewis, V. & Burke, R.E. (1995) 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration, 4, 131-137.
38. Kabuto, H., Yamanushi, T.T., Janjua, N., Takayama, F. & Mankura, M. (2013) Effects of squalene/squalane on dopamine levels, antioxidant enzyme activity, and fatty acid composition in the striatum of Parkinson's disease mouse model. J. Oleo Sci., 62, 21-28.
39. Kadkhodaei, B., Ito, T., Joodmardi, E., Mattsson, B., Rouillard, C., Carta, M., Muramatsu, S.-I., Sumi-Ichinose, C., Nomura, T., Metzger, D., Chambon, P., Lindqvist, E., Larsson, N.-G., Olson, L., Bjorklund, A., Ichinose, H. & Perlmann, T. (2009) Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci., 29, 15923-15932.
40. Kahlert, C., Gaitzsch, E., Steinert, G., Mogler, C., Herpel, E., Hoffmeister, M., Jansen, L., Benner, A., Brenner, H., Chang-Claude, J., Rahbari, N., Schmidt, T., Klupp, F., Grabe, N., Lahrmann, B., Koch, M., Halama, N., Buchler, M. & Weitz, J. (2012) Expression analysis of aldehyde dehydrogenase 1A1 (ALDH1A1) in colon and rectal cancer in association with prognosis and response to chemotherapy. Ann. Surg. Oncol., 19, 4193-4201.
41. Kauhausen, J., Thompson, L.H. & Parish, C.L. (2013) Cell intrinsic and extrinsic factors contribute to enhance neural circuit reconstruction following transplantation in Parkinsonian mice. J. Physiol., 591, 77-91.
42. Kettenmann, H., Hanisch, U.-K., Noda, M. & Verkhratsky, A. (2011) Physiology of microglia. Physiol. Rev., 91, 461-553.
43. Kim, K.H., Jeong, J.Y., Surh, Y.J. & Kim, K.W. (2010) Expression of stress-response ATF3 is mediated by Nrf2 in astrocytes. Nucleic Acids Res., 38, 48-59.
44. Kirik, D., Georgievska, B., Rosenblad, C. & Bjorklund, A. (2001) Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur. J. Neurosci., 13, 1589-1599.
45. Kucinski, A., Wersinger, S., Stachowiak, E.K., Corso, T.D., Parry, M.J., Zhang, J., Jordan, K., Letchworth, S., Bencherif, M. & Stachowiak, M.K. (2013) Neuronal nicotinic receptor agonists ameliorate spontaneous motor asymmetries and motor discoordination in a unilateral mouse model of Parkinson's Disease. Pharmacol. Biochem. Be., 111, 1-10.
46. Lawson, L.J., Perry, V.H., Dri, P. & Gordon, S. (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience, 39, 151-170.
47. Lev, N., Barhum, Y., Ben-Zur, T., Melamed, E., Steiner, I. & Offen, D. (2013) Knocking out DJ-1 attenuates astrocytes neuroprotection against 6-hydroxydopamine toxicity. J. Mol. Neurosci., 50, 542-550.
48. Lundblad, M., Picconi, B., Lindgren, H. & Cenci, M.A. (2004) A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis., 16, 110-123.
49. Marinova-Mutafchieva, L., Sadeghian, M., Broom, L., Davis, J.B., Medhurst, A.D. & Dexter, D.T. (2009) Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease. J. Neurochem., 110, 966-975.
50. McGeer, P.L., Itagaki, S., Boyes, B.E. & McGeer, E.G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology, 38, 1285-1291.
51. Mendez, I., Sanchez-Pernaute, R., Cooper, O., Vinuela, A., Ferrari, D., Bjorklund, L., Dagher, A. & Isacson, O. (2005) Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain, 128, 1498-1510.
52. Morrison, H.W. & Filosa, J.A. (2013) A quantitative spatiotemporal analysis of microglia morphology during ischemic stroke and reperfusion. J. Neuroinflamm., 10, 4.
53. Moses, D., Drago, J., Teper, Y., Gantois, I., Finkelstein, D.I. & Horne, M.K. (2008) Fetal striatum- and ventral mesencephalon-derived expanded neurospheres rescue dopaminergic neurons in vitro and the nigro-striatal system in vivo. Neuroscience, 154, 606-620.
54. Na, S.J., DiLella, A.G., Lis, E.V., Jones, K., Levine, D.M., Stone, D.J. & Hess, J.F. (2010) Molecular Profiling of a 6-Hydroxydopamine Model of Parkinson's Disease. Neurochem. Res., 35, 761-772.
55. Parish, C.L., Finkelstein, D.I., Drago, J., Borrelli, E. & Horne, M.K. (2001) The role of dopamine receptors in regulating the size of axonal arbors. J. Neurosci., 21, 5147-5157.
56. Parish, C.L., Castelo-Branco, G., Rawal, N., Tonnesen, J., Sorensen, A.T., Salto, C., Kokaia, M., Lindvall, O. & Arenas, E. (2008) Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J. Clin. Invest., 118, 149-160.
57. Perez, F.A., Curtis, W.R. & Palmiter, R.D. (2005) Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity. BMC Neurosci., 6, 71.
58. Ribeiro, R.P., Moreira, E.L., Santos, D.B., Colle, D., Dos Santos, A.A., Peres, K.C., Figueiredo, C.P. & Farina, M. (2013) Probucol affords neuroprotection in a 6-OHDA mouse model of Parkinson's disease. Neurochem. Res., 38, 660-668.
59. Rosenblad, C., Kirik, D. & Bjorklund, A. (2000) Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Exp. Neurol., 161, 503-516.
60. Rowland, N. (1978) Meal patterns in rats with nigrostriatal dopamine-depleting lesions, subdiaphragmatic vagotomy, and their combination. Brain Res. Bull., 3, 89-91.
61. Roy, A., Fung, Y.K., Liu, X. & Pahan, K. (2006) Up-regulation of microglial CD11b expression by nitric oxide. J. Biol. Chem., 281, 14971-14980.
62. Sachs, C. & Jonsson, G. (1975) Mechanisms of action of 6-hydroxydopamine. Biochem. Pharmacol., 24, 1-8.
63. Sauer, H. & Oertel, W.H. (1994) Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience, 59, 401-415.
64. Scholzen, T. & Gerdes, J. (2000) The Ki-67 protein: from the known and the unknown. J. Cell. Physiol., 182, 311-322.
65. Schwarting, R.K. & Huston, J.P. (1996) Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog. Neurobiol., 49, 215-266.
66. Sharaf, A., Krieglstein, K. & Spittau, B. (2013) Distribution of microglia in the postnatal murine nigrostriatal system. Cell Tissue Res., 351, 373-382.
67. Song, D.Y., Yang, Y.C., Shin, D.H., Sugama, S., Kim, Y.S., Lee, B.H., Joh, T.H. & Cho, B.P. (2008) Axotomy-induced dopaminergic neurodegeneration is accompanied with c-Jun phosphorylation and activation transcription factor 3 expression. Exp. Neurol., 209, 268-278.
68. Stimpson, C.D., Tetreault, N.A., Allman, J.M., Jacobs, B., Butti, C., Hof, P.R. & Sherwood, C.C. (2011) Biochemical specificity of von Economo neurons in hominoids. Am. J. Hum. Biol., 23, 22-28.
69. Stott, S.R.W., Metzakopian, E., Lin, W., Kaestner, K.H., Hen, R. & Ang, S.-L. (2013) Foxa1 and foxa2 are required for the maintenance of dopaminergic properties in ventral midbrain neurons at late embryonic stages. J. Neurosci., 33, 8022-8034.
70. Tanaka, Y., Nakamura, A., Morioka, M.S., Inoue, S., Tamamori-Adachi, M., Yamada, K., Taketani, K., Kawauchi, J., Tanaka-Okamoto, M., Miyoshi, J., Tanaka, H. & Kitajima, S. (2011) Systems analysis of ATF3 in stress response and cancer reveals opposing effects on pro-apoptotic genes in p53 pathway. PLoS ONE, 6, e26848.
71. Thompson, L., Barraud, P., Andersson, E., Kirik, D. & Bjorklund, A. (2005) Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J. Neurosci., 25, 6467-6477.
72. Thompson, L.H., Grealish, S., Kirik, D. & Bjorklund, A. (2009) Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur. J. Neurosci., 30, 625-638.
73. Ungerstedt, U. (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol., 5, 107-110.
74. Virgone-Carlotta, A., Uhlrich, J., Akram, M.N., Ressnikoff, D., Chretien, F., Domenget, C., Gherardi, R., Despars, G., Jurdic, P., Honnorat, J., Nataf, S. & Touret, M. (2013) Mapping and kinetics of microglia/neuron cell-to-cell contacts in the 6-OHDA murine model of Parkinson's disease. Glia, 61, 1645-1658.
75. Von Voigtlander, P.F. & Moore, K.E. (1973) Turning behavior of mice with unilateral 6-hydroxydopamine lesions in the striatum: effects of apomorphine, L-DOPA, amanthadine, amphetamine and other psychomotor stimulants. Neuropharmacology, 12, 451-462.
76. Walsh, S., Finn, D.P. & Dowd, E. (2011) Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience, 175, 251-261.
77. West, M.J., Slomianka, L. & Gundersen, H.J.G. (1991) Unbiased stereological estimation of the total number of neurons of the rat hippocampus using the optical fractionator. Anat. Rec., 231, 482-497.
78. Winkler, C., Sauer, H., Lee, C.S. & Bjorklund, A. (1996) Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci., 16, 7206-7215.
79. Wolfrum, C., Asilmaz, E., Luca, E., Friedman, J.M. & Stoffel, M. (2004) Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature, 432, 1027-1032.